Ozempic vs Wegovy vs Rybelsus: What's the Difference?

Here is the short answer. Ozempic, Wegovy and Rybelsus all contain the same active ingredient: semaglutide. What separates them is the FDA-approved label each one carries, the doses they reach, and how they are taken. And as of 2026 there is one more wrinkle: the Rybelsus name no longer exists in the United States. Novo Nordisk folded it into the Ozempic brand [1][11].

If you have been prescribed one of these and you are not sure how it differs from the others, this is the plain-English breakdown.

What is semaglutide, and why does it have three names?

Semaglutide is a GLP-1 receptor agonist. It mimics a natural gut hormone that helps the body release insulin when blood sugar rises, slows how fast the stomach empties, and reduces appetite signaling in the brain.

Drug companies file separate applications for separate uses. Novo Nordisk first got semaglutide approved for type 2 diabetes as Ozempic on December 5, 2017 [4]. It then developed a tablet version for diabetes, approved as Rybelsus on September 20, 2019 [4]. A higher-dose injection studied specifically for obesity was approved as Wegovy on June 4, 2021 [5].

So one molecule, three brands, each with its own label, its own dose range and its own price.

In 2026 the picture changed again. Novo Nordisk had developed a reformulated oral semaglutide (approved December 9, 2024 at 1.5, 4 and 9 mg) and decided the Rybelsus name was not pulling its weight. FDA approved Ozempic as the proprietary name for those tablets on January 30, 2026, and the “Ozempic pill” launched nationwide on May 4, 2026 [4][6][11]. A separate, higher-strength oral semaglutide for weight loss launched as Wegovy tablets on January 5, 2026 [7].

What is Ozempic approved for?

Ozempic injection is a once-weekly shot for adults with type 2 diabetes. Its label covers three things [1]:

• Improving blood sugar control, alongside diet and exercise, in adults with type 2 diabetes
• Reducing the risk of major adverse cardiovascular events (cardiovascular death, non-fatal heart attack, non-fatal stroke) in adults with type 2 diabetes and known heart disease
• Reducing the risk of worsening kidney function, end-stage kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease

That last one, added January 28, 2025, is unique in the GLP-1 class [4].

Ozempic is not approved for weight loss. It is also not approved for children.

Doses: The label starts people at 0.25 mg once weekly for four weeks, then moves to 0.5 mg. If more blood sugar control is needed, the label allows stepping up to 1 mg after at least four weeks, and to 2 mg after at least four weeks on 1 mg [1]. The pens come as 2 mg/3 mL (delivers 0.25 and 0.5 mg doses), 4 mg/3 mL (1 mg) and 8 mg/3 mL (2 mg). Each maintenance pen holds four weekly doses.

There is now also a single-dose prefilled syringe version of Ozempic in the label, at 0.25, 0.5 and 1 mg, sold four to a carton [1].

What is Wegovy approved for?

Wegovy injection is the same molecule at higher doses, studied in people with obesity. Its label is the broadest in the class [2]:

• Reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight (added March 8, 2024)
• Reducing excess body weight and maintaining weight reduction long term in adults and children aged 12 and older with obesity, and in adults with overweight plus at least one weight-related condition
• Treating noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced liver fibrosis in adults, under accelerated approval granted August 15, 2025

Doses: The label uses a five-step escalation: 0.25 mg for weeks 1 to 4, 0.5 mg for weeks 5 to 8, 1 mg for weeks 9 to 12, 1.7 mg for weeks 13 to 16, then maintenance from week 17 [2]. The usual maintenance dose for weight reduction is 2.4 mg once weekly, with 1.7 mg as an alternative.

Since March 19, 2026 there is a higher option. Wegovy HD delivers 7.2 mg once weekly [8], and it reached US pharmacies on April 7, 2026. The label allows moving to it only for adults who have tolerated 2.4 mg for at least four weeks and for whom more weight reduction is clinically indicated. In the STEP UP trial, average weight loss at 72 weeks was about 20.7% among people who stayed on treatment, versus about 17.5% for 2.4 mg and about 2.4% for placebo, and 31.2% of people on 7.2 mg lost a quarter of their body weight or more, against 15.3% on 2.4 mg and none on placebo [8].

One caution worth knowing: in STEP UP, about 22% of people on 7.2 mg reported altered skin sensation, such as sensitive skin, tingling or numbness, compared with 6% on 2.4 mg and 0.3% on placebo [8].

Wegovy pens come four to a carton, one preset dose per pen, in six color-coded strengths.

What happened to Rybelsus, and what is the Ozempic pill?

Rybelsus was the original once-daily oral semaglutide for type 2 diabetes at 3, 7 and 14 mg [3]. Novo Nordisk reformulated it into a smaller tablet at 1.5, 4 and 9 mg, then rebranded that version as Ozempic tablets. Novo Nordisk’s marketing lead said publicly that the Rybelsus brand would not be carried forward but the tablets would continue under the Ozempic name [11].

The Ozempic pill went on sale in more than 70,000 US pharmacies on May 4, 2026 [6]. It is approved for the same two things Rybelsus was: blood sugar control in adults with type 2 diabetes, and reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes at high risk [3].

Doses: 1.5 mg once daily for the first 30 days (an initiation dose that the label says is not effective for blood sugar control), then 4 mg for days 31 to 60, then either staying at 4 mg or moving up to 9 mg from day 61 [3].

The label still contains the old Rybelsus strengths and includes a switching table. Rybelsus 7 mg lines up with Ozempic tablets 4 mg, and Rybelsus 14 mg lines up with Ozempic tablets 9 mg. The label also says the two oral products are not substitutable milligram for milligram, and not to switch during the first 30 days [3].

Novo Nordisk has also filed for FDA approval of a 25 mg Ozempic tablet, with a decision reported as expected by the end of 2026 [6].

How do you actually take each one?

The injections (Ozempic and Wegovy) go under the skin of the abdomen, thigh or upper arm, once a week, on the same day each week, at any time of day, with or without food [1][2].

The tablets are stricter. The label says to take one tablet in the morning on an empty stomach with no more than 4 ounces of water, swallow it whole without splitting, crushing or chewing, and then wait at least 30 minutes before eating, drinking anything else or taking other oral medicines [2][3]. That 30-minute window applies to both Wegovy tablets and Ozempic tablets, because both rely on an absorption enhancer that only works in an empty stomach.

If that daily routine sounds hard to keep, that is worth raising with your prescriber before you start, not after.

What about Wegovy tablets versus Ozempic tablets?

This is the most confusing pair, because both are oral semaglutide and both start at 1.5 mg.

	Ozempic tablets	Wegovy tablets
Approved for	Type 2 diabetes; cardiovascular risk in type 2 diabetes	Weight management; cardiovascular risk with obesity or overweight
Strengths	1.5, 4, 9 mg	1.5, 4, 9, 25 mg
Maintenance dose	4 mg or 9 mg	25 mg from day 91
First approved	Reformulation Dec 9, 2024; Ozempic name Jan 30, 2026	Dec 22, 2025

Wegovy tablets carry a fourth strength, 25 mg, which is the maintenance dose for weight management [2]. The label’s escalation is 1.5 mg on days 1 to 30, 4 mg on days 31 to 60, 9 mg on days 61 to 90, then 25 mg from day 91 [2].

The Wegovy tablet label also lays out switching rules with the injection. It says a person taking Wegovy 2.4 mg injection may start 25 mg tablets one week after the last shot, and someone on 25 mg tablets may start the 2.4 mg injection the day after their last tablet [2].

What do they cost?

List prices and what people actually pay are two different numbers. Here is what Novo Nordisk publishes for cash payers in 2026 through NovoCare Pharmacy and its savings offers [9][10]:

Product	Self-pay price per month
Wegovy pen, 0.25 or 0.5 mg (first 2 fills, new patients, through Dec 31 2026)	$199
Wegovy pen, any standard dose after the intro	$349
Wegovy HD 7.2 mg pen	$399
Wegovy pill 1.5 mg	$149
Wegovy pill 4 mg	$199
Wegovy pill 9 mg or 25 mg	$299
Ozempic pen, 0.25 or 0.5 mg (first 2 fills, new patients)	$199
Ozempic pen, 0.25, 0.5 or 1 mg after the intro	$349
Ozempic pen 2 mg	$499
Ozempic pill 1.5 mg	$149
Ozempic pill 4 mg	$199
Ozempic pill 9 mg	$299

People with commercial insurance that covers the drug may pay as little as $25 a month, subject to a maximum saving of $100 a month. Government beneficiaries, including Medicare and Medicaid, are excluded from those copay cards [9][10].

There is also a big list-price change coming. On February 24, 2026 Novo Nordisk announced that effective January 1, 2027 the wholesale acquisition cost will drop to $675 a month, roughly a 50% cut for Wegovy and 35% for Ozempic [12]. The announcement names specific presentations: Wegovy injection 2.4 mg and tablets 25 mg, Ozempic injection 0.5, 1 and 2 mg, and Rybelsus tablets 7 mg or 14 mg. Exact current list prices are published on the federal TrumpRx site, which shows an “Original Price” of $1,349.02 for Wegovy (both the pen and the pill) and $1,027.51 for Ozempic (both the pen and the pill). Rybelsus is not listed on TrumpRx and no company-published figure for it could be confirmed, so treat the roughly $1,000 a month often quoted for Rybelsus as reported rather than confirmed. The company said self-pay prices are not affected by that change, so the people most likely to notice are those on high-deductible plans or coinsurance, whose out-of-pocket cost is tied to list price.

Which one is right for you?

That is a conversation for your healthcare provider, and the honest answer usually comes down to three things:

1. What you are being treated for. If it is type 2 diabetes, Ozempic (injection or pill) is the semaglutide product with that label. If it is obesity or overweight with a related condition, Wegovy (injection or pill) is. If you have type 2 diabetes and obesity, both may be options, and insurance rules often decide.
2. Whether you want a weekly shot or a daily pill. The pills avoid needles but come with the empty-stomach routine. The injections are once a week but need refrigeration and a sharps container.
3. What your plan covers. Diabetes indications are far more widely covered than obesity ones, though the Medicare GLP-1 Bridge that started July 1, 2026 changed that for some Part D enrollees.

One rule applies no matter what: the labels say not to combine any semaglutide product with another semaglutide product or with any other GLP-1 receptor agonist [1][2][3].

Sources

1. OZEMPIC (semaglutide) injection - US Prescribing Information, Novo Nordisk
2. WEGOVY (semaglutide) injection and tablets - US Prescribing Information, Novo Nordisk
3. RYBELSUS and OZEMPIC (semaglutide) tablets - US Prescribing Information, Novo Nordisk
4. Ozempic (semaglutide) FDA Approval History - Drugs.com
5. Wegovy (semaglutide) FDA Approval History - Drugs.com
6. Novo Nordisk’s Ozempic pill soon to be available in the US - PR Newswire, May 1, 2026
7. FDA approves Novo Nordisk’s Wegovy pill - PR Newswire, December 22, 2025
8. FDA approves Novo Nordisk’s new Wegovy HD injection - PR Newswire, March 19, 2026
9. Wegovy price guide - NovoCare
10. Ozempic pill and pen price guide - NovoCare
11. Novo Nordisk’s Rybelsus brand officially retired in US - Fierce Pharma
12. Novo Nordisk announces significant reduction in US list price - PR Newswire, February 24, 2026

This article is general information, not medical advice. Talk to a healthcare provider about which medicine, if any, is appropriate for you.